Immune checkpoint blockade (ICB) has become a standard of care in a subset of solid tumors. Although cancer survivorship has extended, rates of durable response of ICB remain poor; furthermore, cardiac adverse effects are emerging, which impact several mechanical aspects of the heart. Cardio-oncology programs implement a clinical assessment to curtail cardiovascular disease progression but are limited to the current clinical parameters used in cardiology. Pharmacogenomics provides the potential to unveil heritable and somatic genetic variations for guiding precision immunotherapy treatment to reduce the risk of immune-related cardiotoxicity. A better understanding of pharmacogenomics will optimize the current treatment selection and dosing of immunotherapy. Here, we summarize the recent pharmacogenomics studies in immunotherapy responsiveness and its related cardiotoxicity and highlight how patient genetics and epigenetics can facilitate researchers and clinicians in designing new approaches for precision immunotherapy. We highlight and discuss how single-cell technologies, human-induced pluripotent stem cells and systems pharmacogenomics accelerate future studies of precision cardio-oncology.

中文翻译：

---

免疫治疗和免疫相关心脏毒性的药物基因组学。


免疫检查点阻断（ICB）已成为实体瘤子集的护理标准。尽管癌症存活率有所延长，但 ICB 的持久缓解率仍然很低；此外，心脏不良反应正在出现，影响心脏的几个机械方面。心脏肿瘤学项目实施临床评估以遏制心血管疾病的进展，但仅限于心脏病学当前使用的临床参数。药物基因组学提供了揭示遗传性和体细胞遗传变异的潜力，用于指导精准免疫治疗，以降低免疫相关心脏毒性的风险。更好地了解药物基因组学将优化当前免疫疗法的治疗选择和剂量。在这里，我们总结了最近在免疫治疗反应性及其相关心脏毒性方面的药物基因组学研究，并强调患者遗传学和表观遗传学如何帮助研究人员和临床医生设计精准免疫治疗的新方法。我们重点介绍并讨论单细胞技术、人诱导多能干细胞和系统药物基因组学如何加速精准心脏肿瘤学的未来研究。